Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells

Virology

Volumn 370, Issue 2, 2008, Pages 246-254

  Chomont, Nicolas ^a   Hocini, Hakim ^a   Gody, Jean Chrysostome ^b   Bouhlal, Hicham ^a   Becquart, Pierre ^c   Krief Bouillet, Corinne ^a   Kazatchkine, Michel ^a   Bélec, Laurent ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hôpital de l'Amitié   (Central African Republic)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

HEC 1; HIV 1; Neutralization; Transcytosis

Indexed keywords

EPITOPE; GLYCOPROTEIN GP160 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1577; MONOCLONAL ANTIBODY 17B; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 48D; MONOCLONAL ANTIBODY 5F3; MONOCLONAL ANTIBODY F105; MONOCLONAL ANTIBODY F240; MONOCLONAL ANTIBODY F425A1G8; MONOCLONAL ANTIBODY F425B4A1; MONOCLONAL ANTIBODY F425B4E8; MONOCLONAL ANTIBODY IGG1B12; MONOCLONAL ANTIBODY IIIB V3 21; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; BREAST MILK; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SERUM; TRANSCYTOSIS; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PARTICLE;

ANTIBODIES, MONOCLONAL; CELL LINE; DISEASE TRANSMISSION, VERTICAL; EPITHELIAL CELLS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; INFANT, NEWBORN; MILK, HUMAN; MUCOUS MEMBRANE; NEUTRALIZATION TESTS; PREGNANCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 36749022726     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.09.006     Document Type: Article

References (43)

1. Alfsen A., and Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277 28 (2002) 25649-25659
2. Alfsen A., Iniguez P., Bouguyon E., and Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166 10 (2001) 6257-6265
3. Barbas III C.F., Bjorling E., Chiodi F., Dunlop N., Cababa D., Jones T.M., Zebedee S.L., Persson M.A., Nara P.L., Norrby E., et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89 19 (1992) 9339-9343
4. Becquart P., Hocini H., Garin B., Sepou A., Kazatchkine M.D., and Bélec L. Compartmentalization of the IgG immune response to HIV-1 in breast milk. AIDS 13 (1999) 1323-1331
5. Becquart P., Hocini H., Levy M., Sepou A., Kazatchkine M.D., and Belec L. Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J. Infect. Dis. 181 2 (2000) 532-539
6. Belec L., Ghys P.D., Hocini H., Nkengasong J.N., Tranchot-Diallo J., Diallo M.O., Ettiegne-Traore V., Maurice C., Becquart P., Matta M., Si-Mohamed A., Chomont N., Coulibaly I.M., Wiktor S.Z., and Kazatchkine M.D. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184 11 (2001) 1412-1422
7. Bhat S., Spitalnik S.L., Gonzalez-Scarano F., and Silberberg D.H. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 88 16 (1991) 7131-7134
8. Bolmstedt A., Sjolander S., Hansen J.E., Akerblom L., Hemming A., Hu S.L., Morein B., and Olofsson S. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12 3 (1996) 213-220
9. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3 1 (1997) 42-47
10. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10 4 (1994) 359-369
11. Burton D.R., Barbas III C.F., Persson M.A., Koenig S., Chanock R.M., and Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 88 22 (1991) 10134-10137
12. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 5187 (1994) 1024-1027
13. Cavacini L.A., Emes C.L., Power J., Buchbinder A., Zolla-Pazner S., and Posner M.R. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J. Acquir. Immune Defic. Syndr. 6 4 (1993) 353-358
14. Cavacini L.A., Emes C.L., Wisnewski A.V., Power J., Lewis G., Montefiori D., and Posner M.R. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses 14 14 (1998) 1271-1280
15. Cavacini L., Duval M., Song L., Sangster R., Xiang S.H., Sodroski J., and Posner M. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. Aids 17 5 (2003) 685-689
16. D'Souza M.P., Livnat D., Bradac J.A., and Bridges S.H. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J. Infect. Dis. 175 5 (1997) 1056-1062
17. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., Kimani J., Lopalco L., Piconi S., Bwayo J.J., Plummer F., Clerici M., and Hinkula J. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165 9 (2000) 5170-5176
18. Evans, D.J., McKeating, J., Meredith, J.M., Burke, K.L., Katrak, K., John, A., Ferguson, M., Minor, P.D., Weiss, R.A., and Almond, J.W. (1989). An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339(6223), 385-8, 340.
19. Fantini J., Cook D.G., Nathanson N., Spitalnik S.L., and Gonzalez-Scarano F. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. U. S. A. 90 7 (1993) 2700-2704
20. Hocini H., Belec L., Iscaki S., Garin B., Pillot J., Becquart P., and Bomsel M. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res. Hum. Retroviruses 13 14 (1997) 1179-1185
21. Hocini H., Becquart P., Bouhlal H., Chomont N., Ancuta P., Kazatchkine M.D., and Belec L. Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J. Virol. 75 11 (2001) 5370-5374
22. Kage A., Shoolian E., Rokos K., Ozel M., Nuck R., Reutter W., Kottgen E., and Pauli G. Epithelial uptake and transport of cell-free human immunodeficiency virus type 1 and gp120-coated microparticles. J. Virol. 72 5 (1998) 4231-4236
23. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 4 (1992) 2232-2239
24. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 6686 (1998) 648-659
25. Laman J.D., Schellekens M.M., Abacioglu Y.H., Lewis G.K., Tersmette M., Fouchier R.A., Langedijk J.P., Claassen E., and Boersma W.J. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J. Virol. 66 3 (1992) 1823-1831
26. Meng G., Wei X.P., Wu X.Y., Sellers M.T., Decker J.M., Moldoveanu Z., Orenstein J.M., Graham M.F., Kappes J.C., Mestecky J., Shaw G.M., and Smith P.D. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5(+) cells. Nature Med. 8 2 (2002) 150-156
27. Moog C., Spenlehauer C., Fleury H., Heshmati F., Saragosti S., Letourneur F., Kirn A., and Aubertin A.M. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. AIDS Res. Hum. Retroviruses 13 1 (1997) 19-27
28. Moore J.P., and Ho D.D. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67 2 (1993) 863-875
29. Posner M.R., Elboim H., and Santos D. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 6 6 (1987) 611-625
30. Posner M.R., Hideshima T., Cannon T., Mukherjee M., Mayer K.H., and Byrn R.A. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J. Immunol. 146 12 (1991) 4325-4332
31. Posner M.R., Cavacini L.A., Emes C.L., Power J., and Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquir. Immune Defic. Syndr. 6 1 (1993) 7-14
32. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10 12 (1994) 1651-1658
33. Purtscher M., Trkola A., Grassauer A., Schulz P.M., Klima A., Dopper S., Gruber G., Buchacher A., Muster T., and Katinger H. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. Aids 10 6 (1996) 587-593
34. Roben P., Moore J.P., Thali M., Sodroski J., Barbas III C.F., and Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68 8 (1994) 4821-4828
35. Shattock R.J., Griffin G.E., and Gorodeski G.I. In vitro models of mucosal HIV transmission. Nat. Med. 6 6 (2000) 607-608
36. Sullivan N., Sun Y., Sattentau Q., Thali M., Wu D., Denisova G., Gershoni J., Robinson J., Moore J., and Sodroski J. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72 6 (1998) 4694-4703
37. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., and Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67 7 (1993) 3978-3988
38. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
39. Van de Perre P. Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented?. J. Infect. Dis. 179 Suppl 3 (1999) S405-S407
40. Wolbank S., Kunert R., Stiegler G., and Katinger H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77 7 (2003) 4095-4103
41. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., and Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 6686 (1998) 705-711
42. Yahi N., Baghdiguian S., Moreau H., and Fantini J. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J. Virol. 66 8 (1992) 4848-4854
43. Yeaman G.R., White H.D., Howell A., Prabhala R., and Wira C.R. The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res. Hum. Retroviruses 14 Suppl 1 (1998) S57-S62